title: Verapamil improves the outcome after cadaver renal transplantation.
abstract: Because of their favorable effects on renal hemodynamics, calcium antagonists may have a major role in the prevention and management of certain types of acute renal dysfunction. In fact, verapamil (VP) was shown to prevent cyclosporin A (CsA)-induced decreases in RBF in mice and in cadaver renal transplant (CRT) recipients. The study presented here of 59 cadaver renal transplant patients evaluates the outcome from perioperative treatment with VP (N = 30) administered intraoperatively into the renal artery (10 mg) followed by oral administration of 120 mg every 8 to 12 h for 14 days versus no drug (N = 29). Early immunosuppression included azathioprine, corticosteroids, and antilymphocyte globulin with subsequent overlapping with CsA on days 5 and 6. Actuarial graft survival at 1 yr was different when the two groups were compared (P less than 0.05). Estimated graft survival at 1 yr for VP patients was 93.3 compared with 72.4% in control patients. The improved graft survival was most striking in repeat transplants with 90% graft survival at 1 yr for VP recipients versus 37.5% for controls. Compared with controls, VP recipients had significantly improved renal parenchymal diastolic blood flow velocities on the first day after surgery (7.8 versus 5.8 cm/s). By day 7, GFR were greater with VP (44 +/- 29 mL/min) versus controls (28 +/- 22 mL/min). Of VP patients, 67% (18 of 24) had GFR greater than 30 mL/min versus 33% (9 of 26) for control patients. Similarly, on the seventh day, 77% (21 of 30) of VP patients had serum creatinines less than 2.0 mg% versus 34% (10 of 29) for controls.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, University of Texas, Southwestern Medical Center, Dallas 75235-9031.
authors.forename: I
authors.initials: I
authors.lastname: Dawidson
authors.forename: P
authors.initials: P
authors.lastname: Rooth
authors.forename: C
authors.initials: C
authors.lastname: Lu
authors.forename: A
authors.initials: A
authors.lastname: Sagalowsky
authors.forename: K
authors.initials: K
authors.lastname: Diller
authors.forename: B
authors.initials: B
authors.lastname: Palmer
authors.forename: P
authors.initials: P
authors.lastname: Peters
authors.forename: R
authors.initials: R
authors.lastname: Risser
authors.forename: Z
authors.initials: Z
authors.lastname: Sandor
authors.forename: F
authors.initials: F
authors.lastname: Seney
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002102:Cadaver; D016572:Cyclosporine / Q000097:blood; D004231:Diuresis / Q000187:drug effects; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D016030:Kidney Transplantation / Q000502:physiology; D008297:Male; D008875:Middle Aged; D012079:Renal Circulation / Q000187:drug effects; D014700:Verapamil / Q000627:therapeutic use*
chemical_list: D016572:Cyclosporine; D014700:Verapamil